论文部分内容阅读
目的探讨肺表面活性物质预防新生儿呼吸窘迫综合征的临床分析。方法选取汝南县人民医院2008年1月至2011年6月120例早产儿,均有呼吸困难症状,随机分成研究组和对照组。两组患儿都依据实际病情进行对症治疗。对照组仅实施对症治疗,研究组在对症治疗基础上使用固尔苏。结果研究组患儿在用药后的6、24、48 h检测动脉血氧分压、动脉血二氧化碳分压、pH值,与对照组比较均有好转(P<0.05)。研究组呼吸窘迫发生率为10%,对照组为43.33%,研究组低于对照组,差异有统计学意义(P<0.05)。伴随胎龄逐步增加,患儿呼吸窘迫综合征发生率逐步降低(P<0.05)。结论使用肺表面活性物质能够有效避免新生儿呼吸窘迫综合征的出现,有临床推广价值。
Objective To investigate the clinical analysis of pulmonary surfactant in preventing neonatal respiratory distress syndrome. Methods We selected 120 patients with preterm infants from Runan County People’s Hospital from January 2008 to June 2011, who had dyspnea symptoms and were randomly divided into study group and control group. Two groups of children were symptomatic treatment based on the actual condition. The control group only implemented symptomatic treatment, the study group used Guer Su on the basis of symptomatic treatment. Results In the study group, the partial pressure of arterial oxygenation, the partial pressure of arterial carbon dioxide and the pH value of blood were all improved at 6, 24 and 48 h after treatment (P <0.05). The incidence of respiratory distress was 10% in the study group and 43.33% in the control group, which was significantly lower in the study group than in the control group (P <0.05). With the gradual increase of gestational age, the incidence of respiratory distress syndrome in children gradually decreased (P <0.05). Conclusions The use of pulmonary surfactant can effectively prevent the emergence of neonatal respiratory distress syndrome and has clinical value of popularization.